Co-Diagnostics
CODX
81 hedge funds and large institutions have $103M invested in Co-Diagnostics in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 21 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 19
2% more call options, than puts
Call options by funds: $14.7M | Put options by funds: $14.4M
0.1% more ownership
Funds ownership: 0.81% → 0.91% (+0.1%)
6% less funds holding
Funds holding: 86 → 81 (-5)
20% less capital invested
Capital invested by funds: $129M → $103M (-$25.8M)
24% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$7.28M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.75M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.34M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$1.49M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3.93M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.82M |
| 3 |
VF
Virtu Financial
New York
|
-$1.33M |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$1.2M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$532K |
CODX Hedge Fund Activity: Q3 2020 in Review
81 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q3 2020, worth a combined $103M — down 20% from $129M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CODX and 16 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 26 added.
The largest buyer was Nuveen, adding an estimated $7.28M. The largest seller was Citadel Advisors, cutting an estimated $3.93M.
- 81 institutional investors held Co-Diagnostics (CODX) as of Q3 2020, down from 86 in Q2 2020.
- Funds reported $103M of Co-Diagnostics stock for Q3 2020, down 20% quarter-over-quarter.
- 16 funds opened new Co-Diagnostics positions in Q3 2020 and 21 closed out, a net change of -5 holders.
- The largest Co-Diagnostics buyer in Q3 2020 was Nuveen, an estimated $7.28M added.
- The largest Co-Diagnostics seller in Q3 2020 was Citadel Advisors, an estimated $3.93M sold.
Based on aggregated 13F filings for Q3 2020.